newsfilter
← Latest News
GlobeNewswire·

Vincerx Pharma Presents Preclinical VIP943 and VIP924 Posters at ASH 2023

Poster on VIP943, a novel CD123-targeted antibody-drug conjugate (ADC) from our VersAptx™ platform, showcases selectivity, activity, and safety of VIP943 Poster on VIP924, a first-in-class CXCR5-targeted ADC